Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

左乙拉西坦 斯特罗普效应 临床痴呆评级 认知 癫痫 随机对照试验 医学 交叉研究 安慰剂 痴呆 心理学 听力学 物理疗法 精神科 疾病 内科学 认知障碍 替代医学 病理
作者
Keith Vossel,Kamalini G. Ranasinghe,Alexander J. Beagle,Alice La,Kasey Ah Pook,Madelyn Castro,Danielle Mizuiri,Susanne Honma,Nisha Venkateswaran,Mary Koestler,Wenbo Zhang,Lennart Mucke,Michael J. Howell,Katherine L. Possin,Joel H. Kramer,Adam L. Boxer,Bruce L. Miller,Srikantan S. Nagarajan,Heidi E. Kirsch
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:78 (11): 1345-1345 被引量:184
标识
DOI:10.1001/jamaneurol.2021.3310
摘要

Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD).To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD.The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University of California, San Francisco, and the University of Minnesota, Twin Cities, between October 16, 2014, and July 21, 2020. Participants were adults 80 years and younger who had a Mini-Mental State Examination score of 18 points or higher and/or a Clinical Dementia Rating score of less than 2 points. Screening included overnight video electroencephalography and a 1-hour resting magnetoencephalography examination.Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks. Group B received treatment using the reverse sequence.The primary outcome was the ability of levetiracetam treatment to improve executive function (measured by the National Institutes of Health Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research [NIH-EXAMINER] composite score). Secondary outcomes were cognition (measured by the Stroop Color and Word Test [Stroop] interference naming subscale and the Alzheimer's Disease Assessment Scale-Cognitive Subscale) and disability. Exploratory outcomes included performance on a virtual route learning test and scores on cognitive and functional tests among participants with epileptiform activity.Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. A total of 34 adults (21 women [61.8%]; mean [SD] age, 62.3 [7.7] years) with AD were enrolled and randomized (17 participants to group A and 17 participants to group B). Thirteen participants (38.2%) were categorized as having epileptiform activity. In total, 28 participants (82.4%) completed the study, 10 of whom (35.7%) had epileptiform activity. Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures. However, among participants with epileptiform activity, levetiracetam treatment improved performance on the Stroop interference naming subscale (net improvement vs placebo, 7.4 points; 95% CI, 0.2-14.7 points; P = .046) and the virtual route learning test (t = 2.36; Cohen f2 = 0.11; P = .02). There were no treatment discontinuations because of adverse events.In this randomized clinical trial, levetiracetam was well tolerated and, although it did not improve the primary outcome, in prespecified analysis, levetiracetam improved performance on spatial memory and executive function tasks in patients with AD and epileptiform activity. These exploratory findings warrant further assessment of antiseizure approaches in AD.ClinicalTrials.gov Identifier: NCT02002819.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
追寻的访文完成签到,获得积分10
刚刚
思源应助cyan采纳,获得30
1秒前
puff完成签到,获得积分10
3秒前
Flllllll完成签到,获得积分10
5秒前
6秒前
6秒前
QQ完成签到,获得积分10
8秒前
蔚欢发布了新的文献求助10
10秒前
12秒前
Akim应助罗拉采纳,获得10
13秒前
丘比特应助Heartlark采纳,获得10
13秒前
13秒前
延文星完成签到,获得积分20
15秒前
16秒前
xyj6486发布了新的文献求助10
16秒前
18秒前
18秒前
18秒前
bkagyin应助shao采纳,获得10
18秒前
糟糕的日记本完成签到,获得积分10
18秒前
蔚欢完成签到,获得积分10
19秒前
mx发布了新的文献求助10
21秒前
一川烟叶完成签到,获得积分10
21秒前
22秒前
时尚俊驰发布了新的文献求助10
23秒前
23秒前
整齐小松鼠应助mini采纳,获得10
25秒前
恋雅颖月应助liii采纳,获得10
27秒前
罗拉发布了新的文献求助10
29秒前
persist完成签到,获得积分10
30秒前
讨厌科研发布了新的文献求助10
30秒前
沉默曼文发布了新的文献求助40
31秒前
研友_VZG7GZ应助如梦如幻91采纳,获得10
31秒前
32秒前
充电宝应助mx采纳,获得10
33秒前
隐形曼青应助时尚俊驰采纳,获得10
34秒前
35秒前
量子星尘发布了新的文献求助10
35秒前
科研通AI5应助文献采纳,获得30
38秒前
cyan关注了科研通微信公众号
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173